Pancreatic cancer stem cells (CSCs) play a key role in the initiation and progression of pancreatic adenocarcinoma (PDAC). CSCs are responsible for resistance to chemotherapy and radiation*And for cancer metastasis. Recent studies have indicated that RNA methylation, a type of RNA modification, predominantly occurring as m6A methylation, plays an important role in controlling the stemness of cancer cells, therapeutic resistance against chemotherapy and radiation therapy, and their overall relevance to a patient's prognosis. CSCs regulate various behaviors of cancer through cell-cell communication by secreting factors, through their receptors, and through signal transduction. Recent studies have shown that RNA methylation is involved in the biology of the heterogeneity of PDAC. The present review provides an update on the current understanding of RNA modification-based therapeutic targets against deleterious PDAC. Several key pathways and agents that can specifically target CSCs have been identified, thus providing novel insights into the early diagnosis and efficient treatment of PDAC. Contents 1. Introduction 2. Recent studies on pancreatic cancer stem cells 3. Recent studies on RNA methylation in PDAC 4. Significance of RNA methylation in CSCs 5. Possible therapeutic targeting of RNA methylation of CSCs in PDAC 6. Conclusions
CITATION STYLE
Tsuji, Y., Hara, T., Meng, S., Sato, H., Arao, Y., Ofusa, K., & Ishii, H. (2023). Role of RNA methylation in the regulation of pancreatic cancer stem cells (Review). Oncology Letters, 26(2). https://doi.org/10.3892/ol.2023.13922
Mendeley helps you to discover research relevant for your work.